Sec Form 4 Filing - Lane Michael @ IDEXX LABORATORIES INC /DE - 2019-08-05

Every director, officer or owner of more than ten percent of a class of equity securities registered under Section 12 of the '34 Act must file with the U.S. Securities and Exchange Commission (SEC) a statement of ownership regarding such security.

Form 4: Statement of changes in beneficial ownership, filed before the end of the 2nd business day following the day on which a transaction resulting in a change in beneficial ownership.

"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
The following is an SEC EDGAR document rendered as filed.
Here is the list of insider trading transaction codes.

FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person *
Lane Michael
2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [ IDXX]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
Corporate Vice President
(Last)
(First)
(Middle)
C/O IDEXX LABORATORIES, INC., ONE IDEXX DRIVE
3. Date of Earliest Transaction (MM/DD/YY)
08/05/2019
(Street)
WESTBROOK, ME04092
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/05/2019 M 2,010 A $ 62 5,982 ( 1 ) D
Common Stock 08/05/2019 M 638 A $ 79.54 6,620 D
Common Stock 08/05/2019 M 136 A $ 79.54 6,756 D
Common Stock 08/05/2019 M 3 A $ 67.85 6,759 D
Common Stock 08/05/2019 M 6,190 A $ 67.85 12,949 D
Common Stock 08/05/2019 M 4,438 A $ 141.6 17,387 D
Common Stock 08/05/2019 M 1,999 A $ 178.26 19,386 D
Common Stock 08/05/2019 S 12,067 D $ 263.889 ( 2 ) 7,319 D
Common Stock 08/05/2019 S 2,547 D $ 264.2539 4,772 D
Common Stock 08/05/2019 S 3,347 D $ 264.7283 ( 3 ) 1,425 D
Common Stock 592 ( 4 ) I by spouse
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Incentive Stock Option (right-to-buy) $ 62 08/05/2019 M 2,010 ( 5 ) 02/13/2024 Common Stock 2,010 ( 12 ) 0 D
Incentive Stock Option (right-to-buy) $ 79.54 08/05/2019 M 638 ( 6 ) 02/13/2025 Common Stock 638 ( 12 ) 748 D
Non-Qualified Stock Option (right-to-buy) $ 79.54 08/05/2019 M 136 ( 7 ) 02/13/2025 Common Stock 136 ( 12 ) 2,226 D
Incentive Stock Option (right-to-buy) $ 67.85 08/05/2019 M 3 ( 8 ) 02/13/2026 Common Stock 3 ( 12 ) 2,069 D
Non-Qualified Stock Option (right-to-buy) $ 67.85 08/05/2019 M 6,190 ( 9 ) 02/13/2026 Common Stock 6,190 ( 12 ) 4,559 D
Non-Qualified Stock Option (right-to-buy) $ 141.6 08/05/2019 M 4,438 ( 10 ) 02/13/2027 Common Stock 4,438 ( 12 ) 5,948 D
Non-Qualified Stock Option (right-to-buy) $ 178.26 08/05/2019 M 1,999 ( 11 ) 02/13/2028 Common Stock 1,999 ( 12 ) 7,435 D
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Lane Michael
C/O IDEXX LABORATORIES, INC.
ONE IDEXX DRIVE
WESTBROOK, ME04092
Corporate Vice President
Signatures
/s/ Lily J. Lu, Attorney-in-Fact for Michael J. Lane 08/07/2019
** Signature of Reporting Person Date
Explanation of Responses:
( 1 )Includes 20 shares of common stock acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on June 28, 2019.
( 2 )Represents the weighted average sales price of the shares sold ranging from a low of $263.60 to a high of $264.54 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
( 3 )Represents the weighted average sales price of the shares sold ranging from a low of $264.62 to a high of $265.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
( 4 )Held by the reporting person's spouse in an IRA account. The reporting person disclaims beneficial ownership of the shares of common stock held by his spouse except to the extent of his pecuniaryinterest therein.
( 5 )Grant of option to buy 1,005 shares of Issuer common stock that became exercisable on the fifth anniversary of the date of grant without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
( 6 )Grant of option to buy 693 shares of Issuer common stock that vest in five annual installments beginning February 14, 2016 without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
( 7 )Grant of option to buy 1,181 shares of Issuer common stock that vest in five annual installments beginning February 14, 2016 without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
( 8 )Grant of option to buy 2,072 shares of Issuer common stock that vests as to 1 share on February 14, 2017, February 14, 2018 and February 14, 2019, respectively, and as to the remainder on February 14, 2021.
( 9 )Grant of option to buy 10,749 shares of Issuer common stock that vest in five annual installments beginning February 14, 2017.
( 10 )Grant of option to buy 10,386 shares of Issuer common stock that vest in five annual installments beginning February 14, 2018.
( 11 )Grant of option to buy 9,434 shares of Issuer common stock that vest in five annual installments beginning February 14, 2019.
( 12 )Not applicable.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.